Gray Foundation’s Ascendis Pharma A/S ASND Stock Holding History

Gray Foundation’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-51,700	Closed	-$7.72M	–	15
2024 Q3	$7.72M	Hold	51,700	–	–	2.29%	9
2024 Q2	$7.05M	Hold	51,700	–	–	2.16%	10
2024 Q1	$7.82M	Hold	51,700	–	–	2.44%	10
2023 Q4	$6.51M	Buy	+51,700	New	+$5.15M	2.3%	10

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Gray Foundation's ASND Position: Q4 2024 in Review

Gray Foundation sold out of Ascendis Pharma A/S (ASND) in Q4 2024, closing a stake of 51,700 shares — an estimated $7.72M sold.

Gray Foundation first reported a position in ASND in Q4 2023 and held it in 4 quarters. The position peaked at $7.82M in Q1 2024. 214 funds tracked by Wall St. Rank hold ASND as of Q4 2024.

Gray Foundation reported no remaining Ascendis Pharma A/S position as of Q4 2024 after selling out during the quarter.
Gray Foundation sold 51,700 Ascendis Pharma A/S shares in Q4 2024, an estimated $7.72M.
Gray Foundation first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 4 quarters.
Gray Foundation's Ascendis Pharma A/S position peaked at $7.82M in Q1 2024.
214 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2024.

Based on Gray Foundation's 13F filing for Q4 2024, filed 4 Feb 2025.